SLDBSolid Biosciences Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+12% of shares).
Rangebound, no clear trend. Price is −23% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SLDB is trading
Solid Biosciences Inc. is +4.6% over the past year while the S&P 500 is +16%: 11 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −23%
vs 200-day average · a clear downtrend
- RSI (14)
- 34
RSI (14) · neutral
- Below its 52-week high
- 47%
Below its 52-week high
Details›
- Last close2026-10-23
- $5.90
- 1 monthS&P 500 −0.94%
- −21%
- 1 yearS&P 500 +16%
- +4.6%
- 5 yearsS&P 500 +86%
- −83%
- vs 50-day average$8.12
- −27%
- 52-week high
- $11.14
- 52-week low
- $3.93
- Annualised volatility
- 90%
| Year | Return |
|---|---|
| 2026 (year to date) | +4.6% |
| 2025 | +41% |
| 2024 | −35% |
| 2023 | +14% |
| 2022 | −80% |
| 2021 | −77% |
| 2020 | +70% |
| 2019 | −83% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 3 of 8 | −3.5% |
| Feb | 9 | 4 of 9 | +2.8% |
| Mar | 9 | 3 of 9 | −10% |
| Apr | 9 | 3 of 9 | −1.6% |
| May | 9 | 5 of 9 | +3.7% |
| Jun | 9 | 5 of 9 | +13% |
| Jul | 9 | 4 of 9 | +5.4% |
| Aug | 9 | 4 of 9 | +1.4% |
| Sep | 9 | 3 of 9 | −8.8% |
| Oct | 9 | 2 of 9 | −5.7% |
| Nov | 8 | 5 of 8 | −5.6% |
| Dec | 8 | 4 of 8 | +25% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.